Selvita to Exhibit at the 3rd Annual Drug Discovery Chemistry Conference

Krakow, Poland – 11 March 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, today announces that it is a proud sponsor and exhibitor at the upcoming 3rd Annual Drug Discovery Chemistry conference taking place on the 18-19th of March 2019, in London, UK.

 

Throughout the whole event, Selvita team will be available at the booth in the exhibition hall. It is a great opportunity to meet our representatives on-site and learn more about Selvita’s capabilities and expertise in drug discovery.

 

SMi group’s 3rd annual Drug Discovery Chemistry conference aims to discuss emerging techniques, potential drug targets, and advances in the drug discovery field that are driving the pharmaceutical industry into a new era of medicines and therapeutics. This conference aims to provide insight into how these developments can be best utilised in the commercial setting.

 

Additional information is available on the conference website at www.drug-discovery.co.uk

 


Selvita Services Segment

Selvita Services Segment is a drug discovery and development partner for the pharmaceutical and biotechnology industries. It provides integrated drug discovery support starting from hit identification, hit to lead, lead optimization phase up to nomination of a preclinical candidate. The broad range of services includes medicinal and computational chemistry, custom synthesis and scale-up, in vitro pharmacology, structural biology, protein chemistry, ADME/DMPK as well as a comprehensive offer of analytical testing for APIs and drug products. In addition, Selvita Services Segment has extensive expertise in comparability studies of biosimilar drugs. Its laboratories are both GLP- and GMP-certified.

 

About Selvita

Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the U.S (Greater Boston, San Francisco Bay), and in the U.K. (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from the U.S. and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).

 

Media contact:

Malgorzata Syjud
Selvita S.A.
malgorzata.syjud@selvita.com
+48 660 797 362

Click to share!: